Sentry Investment Management’s AbbVie ABBV Stock Holding History

Sentry Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,582	Closed	-$1.05M	–	4
2025 Q4	$1.05M	Hold	4,582	–	–	0.69%	19
2025 Q3	$1.06M	Sell	4,582 -1,064	-19%	-$217K	0.71%	21
2025 Q2	$1.07M	Hold	5,646	–	–	0.59%	23
2025 Q1	$1.05M	Sell	5,646 -1,687	-23%	-$328K	0.71%	24
2024 Q4	$1.3M	Sell	7,333 -1,194	-14%	-$220K	0.62%	25
2024 Q3	$1.68M	Hold	8,527	–	–	0.71%	21
2024 Q2	$1.46M	Sell	8,527 -1,746	-17%	-$289K	0.65%	24
2024 Q1	$1.87M	Buy	10,273 +1,018	+11%	+$175K	0.73%	22
2023 Q4	$1.43M	Sell	9,255 -994	-10%	-$145K	0.62%	25
2023 Q3	$1.53M	Sell	10,249 -2,180	-18%	-$320K	0.73%	21
2023 Q2	$1.68M	Hold	12,429	–	–	0.63%	23
2023 Q1	$1.98M	Buy	12,429 +47	+0.4%	+$7.19K	0.82%	20
2022 Q4	$2M	Buy	12,382 +158	+1%	+$24.2K	0.88%	19
2022 Q3	$1.64M	Buy	12,224 +336	+3%	+$48.2K	0.78%	21
2022 Q2	$1.82M	Sell	11,888 -2,137	-15%	-$327K	0.82%	21
2022 Q1	$2.27M	Sell	14,025 -2,170	-13%	-$315K	0.72%	22
2021 Q4	$2.19M	Buy	16,195 +4,541	+39%	+$536K	0.58%	31
2021 Q3	$1.26M	Sell	11,654 -7,218	-38%	-$825K	0.37%	61
2021 Q2	$2.13M	Hold	18,872	–	–	0.54%	32
2021 Q1	$2.04M	Sell	18,872 -91,802	-83%	-$9.82M	0.56%	33
2020 Q4	$11.9M	Sell	110,674 -3,831	-3%	-$368K	0.6%	32
2020 Q3	$10M	Buy	114,505 +11,849	+12%	+$1.12M	0.56%	36
2020 Q2	$10.1M	Buy	102,656 +7,603	+8%	+$669K	0.61%	30
2020 Q1	$7.24M	Buy	95,053 +2,211	+2%	+$188K	0.53%	47
2019 Q4	$8.22M	Hold	92,842	–	–	0.49%	45
2019 Q3	$7.03M	Hold	92,842	–	–	0.46%	53
2019 Q2	$6.75M	Buy	92,842 +327	+0.4%	+$25.7K	0.45%	50
2019 Q1	$7.46M	Sell	92,515 -6,982	-7%	-$571K	0.52%	43
2018 Q4	$9.17M	Sell	99,497 -2,549	-2%	-$224K	0.66%	33
2018 Q3	$9.65M	Hold	102,046	–	–	0.59%	38
2018 Q2	$9.46M	Sell	102,046 -16,447	-14%	-$1.61M	0.62%	35
2018 Q1	$11.2M	Sell	118,493 -9,262	-7%	-$1.02M	0.68%	32
2017 Q4	$12.4M	Sell	127,755 -827	-0.6%	-$77.9K	0.67%	33
2017 Q3	$11.4M	Buy	128,582 +1,591	+1%	+$121K	0.43%	42
2017 Q2	$9.21M	Sell	126,991 -562	-0.4%	-$37.8K	0.36%	45
2017 Q1	$8.31M	Sell	127,553 -5,831	-4%	-$367K	0.34%	49
2016 Q4	$8.35M	Buy	133,384 +2,925	+2%	+$179K	0.35%	45
2016 Q3	$8.23M	Buy	130,459 +3,280	+3%	+$212K	0.36%	48
2016 Q2	$7.87M	Sell	127,179 -64	-0.1%	-$3.9K	0.35%	52
2016 Q1	$7.27M	Sell	127,243 -1,235	-1%	-$68.8K	0.33%	52
2015 Q4	$7.61M	Buy	128,478 +4,425	+4%	+$255K	0.35%	49
2015 Q3	$6.75M	Buy	124,053 +5,598	+5%	+$364K	0.33%	55
2015 Q2	$7.96M	Buy	118,455 +4,371	+4%	+$285K	0.37%	50
2015 Q1	$6.68M	Buy	114,084 +19,725	+21%	+$1.19M	0.32%	62
2014 Q4	$6.17M	Sell	94,359 -3,668	-4%	-$231K	0.3%	60
2014 Q3	$5.66M	Sell	98,027 -3,765	-4%	-$209K	0.29%	61
2014 Q2	$5.75M	Buy	101,792 +10,472	+11%	+$549K	0.3%	58
2014 Q1	$4.69M	Hold	91,320	–	–	0.25%	66
2013 Q4	$4.82M	Sell	91,320 -17,880	-16%	-$879K	0.26%	65
2013 Q3	$4.88M	Buy	109,200 +28,800	+36%	+$1.28M	0.29%	52
2013 Q2	$3.32M	Buy	+80,400	New	+$3.52M	0.19%	54

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sentry Investment Management's ABBV Position: Q1 2026 in Review

Sentry Investment Management sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 4,582 shares — an estimated $1.05M sold.

Sentry Investment Management first reported a position in ABBV in Q2 2013 and held it in 51 quarters. The position peaked at $12.4M in Q4 2017. 4,097 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Sentry Investment Management reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Sentry Investment Management sold 4,582 AbbVie shares in Q1 2026, an estimated $1.05M.
Sentry Investment Management first reported a position in AbbVie in Q2 2013 and held it in 51 quarters.
Sentry Investment Management's AbbVie position peaked at $12.4M in Q4 2017.
4,097 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Sentry Investment Management's 13F filing for Q1 2026, filed 8 May 2026.